Advanced Search
MyIDEAS: Login

Cost Effectiveness of Oromucosal Cannabis-Based Medicine (Sativex) for Spasticity in Multiple Sclerosis

Contents:

Author Info

  • Lanting Lu

    (Peninsula Technology Assessment Group (PenTAG), Peninsula College of Medicine and Dentistry, University of Exeter, Exeter, UK; Peninsula Collaboration for Leadership in Applied Health Research and Care (PenCLAHRC), Peninsula College of Medicine and Dentistry, University of Exeter, Exeter, UK)

  • Hilary Pearce

    (Public Health Directorate, NHS Devon, Exeter, UK)

  • Chris Roome

    (Public Health Directorate, NHS Devon, Exeter, UK)

  • James Shearer

    (Health Economics Group, Peninsula College of Medicine and Dentistry, University of Exeter, Exeter, UK)

  • Iain A. Lang

    (Peninsula Collaboration for Leadership in Applied Health Research and Care (PenCLAHRC), Peninsula College of Medicine and Dentistry, University of Exeter, Exeter, UK; Public Health Directorate, NHS Devon, Exeter, UK)

  • Ken Stein

    (Peninsula Technology Assessment Group (PenTAG), Peninsula College of Medicine and Dentistry, University of Exeter, Exeter, UK; Peninsula Collaboration for Leadership in Applied Health Research and Care (PenCLAHRC), Peninsula College of Medicine and Dentistry, University of Exeter, Exeter, UK)

Registered author(s):

    Abstract

    Background:Background: Spasticity is common in patients with multiple sclerosis (MS) and is a major contributor to disability. Sativex, an oromucosal spray containing cannabis-based medicinal products, has been found to be effective in reducing spasticity symptoms. Abstract: Objective:Objective: Our objective was to estimate the cost effectiveness of Sativex plus oral anti-spasticity medicines compared with the current standard treatment for moderate or severe spasticity in MS in the UK. Abstract: Methods:Methods: A Markov model was used to assess the costs and benefits of Sativex plus oral anti-spasticity medicines or current standard treatment based on their effects on the quality of life of patients. The main outcome was the incremental cost-effectiveness ratio (ICER) in terms of costs per additional QALY gained over 5 years of treatment. One-way, multi-way and probabilistic sensitivity analyses were conducted to explore the impact of uncertainties on the findings. Abstract: Results:Results: In the base case, Sativex plus oral anti-spasticity medicines resulted in incremental costs of £7600 and a QALY gain of 0.15 per person over 5 years (ICER - £49 300 per QALY).[year 2009 data for costs]. Findings were sensitive to the costs of Sativex (price and dose) and differences in utilities between responders and non-responders. Abstract: Conclusions:Conclusions: Using a willingness-to-pay threshold of £30 000 per QALY, Sativex appears unlikely to be considered cost effective by UK funders of healthcare for spasticity in MS. This is unfortunate, since it appears that Sativex use is likely to benefit some patients in the management of this common consequence of MS.

    Download Info

    If you experience problems downloading a file, check if you have the proper application to view it first. In case of further problems read the IDEAS help page. Note that these files are not on the IDEAS site. Please be patient as the files may be large.
    File URL: http://PharmacoEconomics.adisonline.com/pt/re/pec/pdfhandler.00019053-201230120-00006.pdf
    Download Restriction: Pay per view

    File URL: http://PharmacoEconomics.adisonline.com/pt/re/pec/fulltext.00019053-201230120-00006.htm
    Download Restriction: Pay per view

    As the access to this document is restricted, you may want to look for a different version under "Related research" (further below) or search for a different version of it.

    Bibliographic Info

    Article provided by Springer Healthcare | Adis in its journal PharmacoEconomics.

    Volume (Year): 30 (2012)
    Issue (Month): 12 ()
    Pages: 1157-1171

    as in new window
    Handle: RePEc:wkh:phecon:v:30:y:2012:i:12:p:1157-1171

    Contact details of provider:
    Web page: http://pharmacoeconomics.adisonline.com/

    Related research

    Keywords: Antispastics; Baclofen; Botulinum-toxins; Cost-utility; Multiple-sclerosis; Nabiximols; Probabilistic-sensitivity-analysis.;

    Find related papers by JEL classification:

    References

    No references listed on IDEAS
    You can help add them by filling out this form.

    Citations

    Lists

    This item is not listed on Wikipedia, on a reading list or among the top items on IDEAS.

    Statistics

    Access and download statistics

    Corrections

    When requesting a correction, please mention this item's handle: RePEc:wkh:phecon:v:30:y:2012:i:12:p:1157-1171. See general information about how to correct material in RePEc.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: (Dave Dustin).

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If references are entirely missing, you can add them using this form.

    If the full references list an item that is present in RePEc, but the system did not link to it, you can help with this form.

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your profile, as there may be some citations waiting for confirmation.

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.